This site is intended for healthcare professionals

FDA approves Nuzyra oral-only dosing regimen for the treatment of community-acquired bacterial pneumonia (CABP).- Paratek Pharma

Read time: 1 mins
Last updated:8th Jun 2021
Published:7th Jun 2021
Paratek Pharmaceuticals, Inc. announced that the FDA has approved the Company's supplemental New Drug Application (sNDA) for the oral-only dosing regimen of Nuzyra for the treatment of adults with CABP.
Condition: Infectious Diseases /CABP
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest